IN BRIEF: RTW Biotech welcomes GSK deal to buy RAPT Therapeutics
RTW Biotech Opportunities Ltd - Guernsey-based investor in the life sciences sector - Notes GSK PLC's announcement on Tuesday that it has agreed to acquire RAPT Therapeutics Inc. Says RAPT, a Californian biopharmaceutical company developing therapies for inflammatory and immunologic diseases, represented 0.15% of its net asset value as of December 31. The all-cash transaction values RAPT at USD2.2 billion, with shareholders to receive USD58 per share. RTW says the price represents a 65% premium to RAPT's closing price on Monday. Read More